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Abstract
Purpose National initiatives, such as the UK Improving
Access to Psychological Therapies program (IAPT),
demonstrate the feasibility of conducting empirical mental
health assessments on a large scale, and similar initiatives
exist in other countries. However, there is a lack of
international consensus on which outcome domains are
most salient to monitor treatment progress and how they
should be measured. The aim of this project was to propose
(1) an essential set of outcome domains relevant across
countries and cultures, (2) a set of easily accessible patient-
reported instruments, and (3) a psychometric approach to
make scores from different instruments comparable.
Methods Twenty-four experts, including ten health out-
comes researchers, ten clinical experts from all continents,
two patient advocates, and two ICHOM coordinators
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worked for seven months in a consensus building exercise
to develop recommendations based on existing evidence
using a structured consensus-driven modified Delphi
technique.
Results The group proposes to combine an assessment of
potential outcome predictors at baseline (47 items: demo-
graphics, functional, clinical status, etc.), with repeated
assessments of disease-specific symptoms during the
treatment process (19 items: symptoms, side effects, etc.),
and a comprehensive annual assessment of broader treat-
ment outcomes (45 items: remission, absenteeism, etc.).
Further, it is suggested reporting disease-specific symp-
toms for depression and anxiety on a standardized metric to
increase comparability with other legacy instruments. All
recommended instruments are provided online (www.
ichom.org).
Conclusion An international standard of health outcomes
assessment has the potential to improve clinical decision
making, enhance health care for the benefit of patients, and
facilitate scientific knowledge.
Keywords Depression  Anxiety  Patient-reported
outcomes  Health-related quality of life  Standardization 
Outcome Set
Introduction
Treatment of depression and anxiety disorders remains one
of today’s most important health challenges. Combined,
these two conditions represent the most years lived with
disability of any disease [1]. Their direct treatment and
indirect impact on other conditions contributes to a sub-
stantial portion of health care spending [2]. According to
the most recent data available, depression in the United
States alone costs society $210 billion per year, including
direct medical costs (45%), suicide-related mortality costs
(5%), and workplace costs (50%) [3].
A variety of treatment options have been proven effec-
tive in reducing symptom burden and improving func-
tioning for patients with depression or anxiety [4]. These
include several types and combinations of psychological
interventions and antidepressant medications [5]. Although
the general effectiveness of these treatments has been
established, the questions of what works for whom and
how to sequence and combine treatments remain to be
addressed [6].
There are many well-validated health outcome assess-
ments available to monitor the treatment process of mental
health conditions [7]. However, utilization of empirical
evidence in clinical practice to inform clinical decision
making is still a rare occurrence.
There are a number of reasons why the empirical
assessment of mental health domains is less common
compared to the assessment of biomedical markers. Several
methodological issues have been discussed, including
insufficient measurement precision, limited measurement
range, high respondent burden, inadequate physician
reports, and the impracticality of using paper-and-pencil
assessments within daily clinical routine [8]. Another
important issue is that for many of the most relevant mental
health domains there are several competing tools, and even
if the same constructs are measured results from different
instruments are difficult to compare [9]. Like in many other
fields, lack of standardization seriously hinders communi-
cation among patients, practitioners, and scientists.
To date, the most comprehensive effort to initiate stan-
dardized outcome assessments for the treatment of mental
health disorders has come from the United Kingdom
(‘‘Improving Access to Psychological Therapies’’ (IAPT))
[10]. Routine collection of patient-reported outcomes
(PRO) was coupled to a new program of expanding access
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to psychotherapists [11]. The success of the program
(63.7% achieved reliable improvement or recovery) was
celebrated, and has supported the case for its funding and
led to similar initiatives in other health systems [12–14].
Unfortunately, as outcome monitoring initiatives prolifer-
ate, no consensus exists as to which measures to include in
such programs and many are now developing without
awareness of existing global practices. Lack of data stan-
dards between programs hinders comparisons of program
effectiveness or opportunities for data aggregation and
research.
To address this need for a consolidated recommendation
on what outcomes are essential to track for patients with
depression and anxiety, we convened an international,
multi-disciplinary Working Group under the leadership of
the International Consortium for Health Outcomes Mea-
surement (ICHOM).
Method
The Working Group
A Working Group was organized by ICHOM (www.ichom.
org), a non-profit organization focused on the development
of standardized datasets of outcomes and case-mix factors
for use in clinical practice. Working Group members were
selected by purposive sampling [15] based on their
expertise with the aim of representing a wide clinical,
scientific and cultural background. Members (n = 24)
included patient representatives (LL, DS), measurement
experts (EdB, EH, SN, PP, CS, MR), clinical (LB, TF, DM,
RR, GR, KWB), social and public health researchers (AC,
DC, PE, MK, AL, VP), clinicians (AO, LB, TF, MK, AL,
DM, HP, RR, GR, MR) and coordinators (LvM, CSt). The
final group included members from twelve countries:
Australia, Brazil, Canada, Chile, Germany, India, Japan,
the Netherlands, Sweden, Uganda, the United Kingdom,
and the United States. Patient representatives participated
in the development process of the standard set in every
step, with equal voting rights, and contributed actively to
the discussion.
Development of the standard set
A structured consensus-driven modified Delphi technique
was used to develop the ICHOM standard set. The Delphi
approach is an iterative, multistage process with the aim of
transforming opinion into group consensus [16]. The
technique was developed by ICHOM and successfully
applied to create outcome standards for a growing number
of health conditions (www.ichom.org) [17–23]. Over a
period of eleven months, the Working Group met monthly
by teleconference. Preparation of the meetings and surveys,
guided by the ICHOM framework, followed a pre-defined
set of activities: (1) prioritizing outcome domains, (2)
selecting outcome measures, (3) prioritizing case-mix
domains, and (4) selecting case-mix definitions. Prioriti-
zation of outcome domains and case-mix variables was
carried out by allocating all variables to the outcome
measures hierarchy developed by Porter [24]. In prepara-
tion of the teleconference calls, a comprehensive literature
search using common databases (PubMed, EMBASE,
Medline, PsycINFO) and a specific database for clinical
outcome assessments (www.proqolid.org) was conducted
for each outcome domain or case-mix factor, augmented by
interviews with the patient representatives in the Working
Group and selected experts (see Fig. 1 for a detailed search
strategy, see Online Appendix 1 for a list of all instruments
found, see ‘‘Results’’ section for a summary). During the
teleconferences, the collated evidence was presented. Fol-
lowing each teleconference, the discussion content (quali-
tative data) was collated into online surveys (quantitative
data). Working Group members were then asked to submit
their feedback; final votes were carried out via an anony-
mous web questionnaire. Content was included if a two-
third majority vote (66%) was reached, items rated below
50% were excluded, results between 50 and 66% were
subject to further discussion in subsequent teleconferences
and re-voted upon until consensus for in- or exclusion was
reached. Results were fed back to the group in summarized
form. Within eleven months of the duration of the project,
seven surveys were conducted with response rates between
70 and 100%. Online surveys were compiled using
Qualtrics online survey platform (www.qualtrics.com).
The final standard set was approved by all members of the
Working Group. Explanation of the consensus process
(Online Appendix 2) and voting results (Online Appendix
3–7) are provided as online supplements.
In selecting measures for prioritized domains, available
measurement tools covering the selected domains were
reviewed. If there were no validated tools for prioritized
case-mix variables, ad hoc items were generated based on
existing instruments (IAPT UK [10], Canadian Community
Health Survey [25]) modified to be appropriate for low
health literacy levels [26]. This was not the case for out-
come instruments (i.e., scales) but only for 13 single items
included for case-mix adjustment collecting information
about the patients’ medical history, such as the duration of
symptoms or prior episodes of their disease (Table 1). Pre-
defined inclusion criteria for instruments or single items
comprised the following criteria: (1) extent of domain
coverage (extent to which the instrument or item covers the
a priori defined domains, for example, whether a ques-
tionnaire or set of questionnaires measuring functioning
completely covered physical, social and occupational
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functioning or only partially), (2) psychometric properties
(validity, reliability, responsiveness), (3) clinical inter-
pretability (if instrument was validated with clinical and
non-clinical samples), (4) feasibility (scale length, com-
plexity, health literacy level), (5) number of available
translations (including existence of cross-cultural
validation), and (6) absence of license fees. In addition,
instruments had to be available at least in English, and
instruments and items had to be applicable for patients
from age 14 and above. The selection process for the
outcome measures is further illustrated in Fig. 1.
Fig. 1 Search strategy and selection process for instruments consid-
ered for the D?A standard set (modified PRISMA flow diagram).
Stepwise selection based on literature review, monthly teleconference
calls, and subsequent online surveys. Initial search term for scientific
databases: ‘‘(depress* [TITLE] OR anxiety [TITLE] OR PTSD
[TITLE] OR post-traumatic stress disorder [TITLE] OR dysthymia
[TITLE] OR GAD [TITLE] OR SAD [TITLE] OR agoraphobia
[TITLE] OR panic [TITLE] OR obsessive compulsive [TITLE] OR
OCD [TITLE]) AND (instrument [TITLE] OR patient-reported
outcome [TITLE] OR questionnaire [TITLE])’’. IAPT UK = Im-
proving Access to Psychological Therapies program by the National
Institute of Health in the United Kingdom; PHQ-9 = Patient Health
Questionnaire 9-item version; GAD-7 = PHQ module for assessment
of General anxiety disorder, 7-items; WHODAS = WHO Disability
Assessment Schedule
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Table 1 Adapted or newly developed items in the standard set
# Variable Item Response options
1 Age What is your date of birth? Date
2 Sex Please indicate your sex at birth Male, female, do not want to answer
3 Educational level Please indicate highest level of schooling completed ISCED 1997, Country specific
4 Living status Which statement best describes your living arrangements? (a) With partner/spouse/family/friends
(b) Alone
(c) Nursing home/hospital/long-term care home
(d) Other
5 Work status What is your work status? (a) Unable to work (due to a condition other than
depression or anxiety)
(b) Unable to work (due to depression or anxiety)
(c) Not working by choice (student, retired,
homemaker)
(d) Working part-time
(e) Seeking employment (I consider myself able to
work but cannot find a job)
(f) Working full-time
6 Prior episodes of
depression/anxiety
Did you experience similar episodes of depression or
anxiety before in your life?
(a) This is my first episode
(b) I had one similar episode before the current one
(c) I had several similar episodes before the current
one
(d) My symptoms of depression do not occur in
episodes
7 Duration of symptoms How many months have you been experiencing symptoms
of depression/anxiety?
# Of months
8 Prior/current treatment During the last year, did you receive any of the following
treatments for depression/anxiety?
Response for each: medication, psychological treatment,
other
(a) No
(b) 1–3 months
(c) 3–6 months
(d) more than 6 months
9 Outcome expectancy How successful do you think your current therapy will be in
reducing your symptoms?
(a) Not at all successful
(b) Somewhat successful
(c) Moderately successful
(d) Very successful
10 Medication side effects Did you experience medication side effects?
If Yes, please indicate which side effects you have
experienced:
yes/no
(a) Weight gain
(b) Sexual dysfunction
(c) Sleep disturbances
(d) Dry mouth
(e) Drowsiness/sedation
(f) Cardiovascular side effects (e.g. palpitations)
(g) Gastrointestinal side effects (e.g. diarrhea,
nausea, vomiting)
(h) Other:
11 Absenteeism How many working days have you missed within the last
month due to illness?
# of days
12 Recurrent episode Did you experience any episodes of depression/anxiety
within the last year?
(a) I experienced no episodes
(b) I had one episode
(c) I had several episodes
(d) My symptoms of depression do not occur in
episodes
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Results
Scope
Given the aim to recommend standard assessments for
depression and anxiety, we first defined the target disor-
ders. The group decided to not limit the recommendations
to a single disorder but to consider the following spectrum
of diseases: Major Depressive Disorder, Depressive
Disorder—Not Otherwise Specified, Adjustment Disorder/
Depressive Adaptive Disorder, Dysthymia, General Anxi-
ety Disorder, Social Anxiety Disorder, Agoraphobia, Panic
Disorder, Post-Traumatic-Stress Disorder, and Obsessive
Compulsive Disorder. The aim was that the suggested
outcome variables should be responsive to therapy effects
from established interventions. Recommendations were
limited to adults including adolescents above the age of
14 years as there was agreement across working group
members that onset of depression in younger people often
occurs before the age of 18 years. Evidence suggests good
validity for common adult measures for adolescents (see
Online Appendix 3) [27].
Outcome domains
Following the ICHOM framework [24], the Working
Group agreed on four general treatment outcomes:
(a) symptom burden, (b) functioning, (c) disease progres-
sion and treatment sustainability, and (d) potential side
effects of treatments (Tables 2, 3, Online Appendix 4, 6,
reference guide at www.ichom.org).
Prioritization of treatment outcomes (teleconference #1,
see Online Appendix 4) based on Porter’s outcome mea-
sures hierarchy [24, 28] resulted in the exclusion of the
domains ‘‘survival’’ and ‘‘long-term consequences of
therapy’’ as they were felt to be less relevant for depression
or anxiety. ‘‘Degree of health achieved or maintained,’’
‘‘Time to recovery,’’ ‘‘disutility of care or treatment pro-
cess,’’ and ‘‘sustainability of health’’ were included
resulting in 13 final outcomes (i.e., symptoms of depres-
sion/anxiety, social functioning, medication side effects,
etc.; see Online Appendix 4).
A comprehensive literature review to find potential
instruments measuring these outcomes was carried out
between July 2nd and 21st, 2014 (Fig. 1). After removing
duplicates, instruments for children, instruments in other
languages than English, and instruments assessing depres-
sion or anxiety as a comorbidity of other disorders (e.g.,
depression following a stroke), a total of 80 instruments
were retained which assess depressive, general or specific
anxiety symptoms, or disease-related functioning. These
instruments were reduced further based on aforementioned
inclusion criteria resulting in 23 instruments (see Fig. 1 and
‘‘Methods’’ section).
Symptom burden
Fifteen scales were analyzed in detail based on aforemen-
tioned considerations (Fig. 1, Online Appendix 4, 6), dis-
cussed within the working group (teleconference #2) and
voted on. The depression subscale of the Patient Health
Questionnaire [29], the 9-item PHQ-9, was selected to
measure depressive symptoms for patients with depressive
disorders, and its anxiety subscale Generalized Anxiety
Disorder 7-Item scale (GAD-7) [30] was chosen to measure
anxiety symptoms in patients with anxiety spectrum dis-
orders. These scales were selected due to their excellent
psychometric properties, the large amount of translations
available, the availability of population norms, cross-cul-
tural validation for a large number of languages (www.
phqscreeners.com), and their acceptance in the scientific
community [30].
In making this recommendation, we recognized that the
GAD-7 is a generic measure of anxiety developed primarily
to assess generalized anxiety disorders (GAD) and may fail
to properly measure the impact of treatment on more
specific anxiety disorders (e.g., in cases where avoidance
reduces the anxious affect as in housebound agoraphobia or
in cases with intrusive memories, compulsions or avoid-
ance). For this reason, institutions desiring a more compre-
hensive assessment of specific anxiety disorders may wish to
complement the GAD-7 with additional instruments. In
Online Appendix 8 and 9 (online supplements), the instru-
ments used in the IAPT program are listed for reference
purposes. We did not include these measures as part of the
formal standard set as most remain research instruments and
would benefit from additional optimization (e.g. reduction of
item burden) before use in clinical practice.
Table 1 continued
# Variable Item Response options
13 Overall success of
treatment
Has the treatment of your depression/anxiety over the last
year been successful?
(a) Very much
(b) Moderately
(c) Somewhat
(d) Not at all
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Recent studies and initiatives have emerged using item
response theory methods to develop large item banks
allowing to score different instruments measuring the same
construct on one common—instrument-independent—
metric [9, 31, 32]. These item banks provide an opportunity
to move away from instrument defined measurements to
construct defined measurements; similar to the assessment
of biomedical markers, where for example, measurement
of an HbA1c level is independent from the manufacture of
the laboratory device. There are several efforts in this
respect (www.common-metrics.org), the one receiving the
most public support today is the development of the
Patient-Reported Outcomes Measurement Information
System (PROMIS, www.nihpromis.org) [33], cross-fun-
ded by all National Institutes of Health the U.S.. Thus, to
facilitate comparisons of our current recommendations
with other existing instruments and to ensure its forward-
compatibility we propose that raw scores of the PHQ-9,
GAD-7 should be converted to the common-metric pro-
vided by the PROMIS initiative (referred to as ‘‘PROMIS
metric’’ throughout the text). This can be easily achieved
using look-up tables (Table A2 in [31, 32], also included in
the reference guide) or freely available software (www.
common-metrics.org).
Functioning
Given the large body of evidence suggesting that depres-
sion and anxiety disorders are associated with impaired
functioning, the Working Group recommended its inclu-
sion in the standard set [34]. However, functioning is a
broad domain with often lengthy assessments, which
reduces feasibility in clinical practice, particularly in
community-based, frontline care settings. To counterbal-
ance these considerations, the Working Group recom-
mended a more comprehensive assessment at baseline and
annual follow-up and a shorter one-item measure during
treatment. Due to its availability in many languages and
general population reference data, we selected the World
Health Organization Disability Schedule 2.0 (WHODAS
2.0) 12-item self-rating version to measure physical, social,
and occupational functioning (Tables 2, 3, Online
Table 3 Assessment sets, domains, number of items, and estimated time for completion of the depression and anxiety standard set
BL (baseline set) TM (treatment monitoring set) AA (annual outcome assessment)
Case-mix
factors
Age
Sex
Educational level
Living status
Work status
Social Support
Comorbidities
Prior episodes of depression/
anxiety
Duration of symptoms
Prior treatment
Outcome expectancy
Current treatment Living status
Work status
Comorbidities
Prior and current treatment
Social support
Outcome expectancy
Outcomes Symptom burden (PHQ-9 and
GAD-7)
Medication side effects
Functioning (WHODAS 2.0)
Absenteeism
Symptom burden (PHQ-9 and GAD-7)
Single Functioning item (PHQ-9/GAD-7
supplement)
Medication side effects
Time to recovery
Symptom burden (PHQ-9 and
GAD-7)
Medication side effects
Recurrent episode
Functioning (WHODAS 2.0)
Absenteeism
Overall success of treatment
Change of mental health status RCI
# of Items 47 19 45
Time [min]* 13 5 12
WHODAS 2.0 The World Health Organization Disability Assessment Schedule 2.0 12-Item Version, RCI reliable change index, PHQ-9 Patient
Health Questionnaire-9
* Information on time to complete surveys varies between 25 and 5 items per minute according to source. A mean of 3.75 was employed to
calculate durations
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Appendix 8, 9) at baseline and at annual follow-ups
[35, 36]. For ongoing treatment, a single item from the
PHQ-9 (additional item) that assesses the difficulties of
daily life functioning patients attribute to their symptoms,
which has been found to correlate highly with other longer
functioning scales was selected [29, 34].
Disease progression and treatment sustainability
Depression and anxiety are remitting and relapsing in
nature, prompting the Working Group’s desire to capture
the time to recovery and sustainability of recovery over
time. We recommend capturing time to recovery using the
reliable change index (RCI) on symptom burden assess-
ments that are collected throughout the process of care. The
RCI helps determine whether changes in instrument score
indicate a clinically meaningful (reliable) alteration of
symptoms rather than an artifact of measurement error
(Table 2, Online Appendix 8) [37, 38]. To assess sustain-
ability of recovery, in addition to the annual assessment of
symptom burden and functioning, we developed a single
item regarding patients’ self-report of depressive episodes
during the past year (Table 1, #6, and #12). Workplace
absenteeism, a primary driver of overall economic costs
was also prioritized for inclusion, defined as the number of
days missed during the last month due to illness (Table 1,
#11). Finally, we prioritized patients’ perceived success of
treatment as this appraisal is one of the best indicators for
good treatment outcome (Table 1, #9) [39].
Treatment side effects
Primarily informed by the experience of patients in the
Working Group, treatment side effects were included in the
Standard Set. Mild side effects with intake of antidepressants
are very common and we recognize that clinicians often
accept these side effect profiles, but the awareness of side
effects and the improved ability to project which side effects a
patient was most likely to experience, was considered of
sufficient importance to warrant their inclusion. As no short
but well-validated instrument was found for assessing treat-
ment side effects, we developed a simple assessment for
proposed use and future validation (Table 1, #10).
Baseline characteristics
A primary goal of this effort is to ensure comparisons of
treatment outcomes across providers. As such, we sought to
identify a minimum set of baseline characteristics to allow
for future case-mix adjustments. In identifying case-mix
factors, the Working Group agreed on the four following
areas: demographics, baseline functional status, baseline
clinical status, and prior treatments.
Demographic factors
Age, sex, socioeconomic status (SES), and living situation
were included as key demographic variables and defined in
line with other ICHOM Standard Sets (Table 1, #1–4).
Patient-reported highest level of education can be collected
as a surrogate measurement of SES [40], as patients gen-
erally feel comfortable reporting this information and it can
be compared across countries using the International
Standard Classification of Education [41]. Individual
countries may elect to complement education level with
additional measures of SES if available, such as income-
based or postal-code based measures. Although influence
of living situation on outcome has not yet been systemat-
ically investigated, clinical experience indicates that it
influences treatment effect. We recommend collecting
living situation using a simple assessment routinely col-
lected across the National Health Service PROMs program
[42].
Baseline functional status
We recommend collecting all outcome measures at base-
line, including the WHODAS 2.0 to allow for changes in
status to be calculated over time. We also recommend
collecting work (Table 1, #5) status and social support at
baseline as these factors are predictors of treatment success
[43]. As with other ICHOM Standard Sets, a single item
was used to assess work status. To capture social support,
we recommend using four items of the ‘‘Medical Outcomes
Study—Social Support Survey’’ (MOS-SSS) [44]. This
instrument yielded a stable factor structure even with a
reduced number of items and within assessments in low
and middle income countries [45].
Baseline clinical status
To allow segmentation of patients for analyses, we rec-
ommend recording clinical diagnoses using established
classification systems (i.e., ICD or DSM). In addition, we
recommend capturing mental and general medical comor-
bidities, as they have been shown to influence treatment
outcomes [46]. We recommend using the Self-administered
Comorbidity Questionnaire (SCQ) extended by a list of
mental comorbidities to capture these factors [47, 48].
Although relatively unknown, the SCQ has shown to pre-
dict functional outcome with equivalence to medical record
based Charlson Comorbidity Index [49]. Patients’ expec-
tation regarding success of their treatment is also strongly
related to treatment outcome and we elected to include an
adapted single item from the credibility/expectancy ques-
tionnaire: ‘‘How successful do you think will the therapy
be in reducing your symptoms?’’ [39]. Adaptation of this
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questionnaire to a single item in previous studies has
shown good applicability [50].
Prior treatment and course of disease
Prior treatments and duration of disease have also been
shown to influence treatment outcomes [51]. We developed
a single item to capture the use of mental health treatments
(i.e., medication, psychotherapy, or other) during the last
year (Table 1, #8) as well as single items on prior episodes
of depression and duration (in months) of the current epi-
sode (Table 1, #6–7).
Assessment time points
Throughout the consensus process, the assessment
scheme was revised twice. Initial online voting supported
the recommendation of monthly assessments during treat-
ment, assessments on every third month during the first
year after completion of treatment, and a two-year follow-
up period. Our final recommendation arose from the
thinking that beginning and duration of treatments may
vary significantly across patients and that completeness of
pre-post treatment data could be improved by frequent
assessments during active treatment. In addition, some
fixed (annual) assessments would allow for better compa-
rability between patient groups.
Finally, we designed the standardized set with a baseline
assessment and two follow-up modules, one focused on
capturing changes in symptom burden during active treat-
ment (treatment monitoring (TM)), and a more compre-
hensive annual outcome assessment (annual assessment
(AA)) to allow for research and benchmarking activities
with data collected at the same time points. The IAPT
program has shown that regular data collection during a
course of treatment helps guide therapy and ensures very
high (up to 97%) pre-post data completeness [52]. In order
to be more helpful in clinical practice, we designed the
short TM as a set of variables that are very succinct and
focused to inform clinical decision making (Fig. 2).
Although it is usually recommended the AA be collected at
least annually, we do encourage institutions that wish to
conduct more frequent follow-up to do so. As some base-
line characteristics may change over the course of the
treatment process (living status, work status, comorbidities,
prior and current treatment, social support, and outcome
expectancy), we also recommend they be updated annually.
Reference guide
A freely available reference guide that further describes
each instrument and provides detailed information about
how to calculate scale scores including PROMIS conver-
sion tables and RCIs is accessible online (www.ichom.org).
Discussion
As health systems around the world shift their attention to
measuring the value (outcomes relative to cost) of the
services they fund and deliver, there is a need to align on
what constitutes the outcomes most relevant to patients. An
internationally standardized dataset would satisfy the
diverse needs of patients, clinicians, researchers, and policy
makers, including: (1) improved communication and
decision making between patients and their providers on
what treatment plans would best suit their needs, (2)
improved monitoring of the impact of treatments across
populations of patients, including informing comparative
effectiveness studies, and (3) consumer-facing comparisons
of the relative outcome performance of different care
facilities.
For patients with mental health disorders, such a dataset
will mainly rely on the patients’ self-assessment. However,
although patient-reported outcomes have been receiving
more attention over the last years, the measurement of
PROs is still not as established as the measurement of
T0 1 year 2 years Optional 
extension…
Begin data collection
Baseline assessment (BL)
Treatment monitoring (TM)
Annual assessment (AA)
T0
Initial visit
Active treatment stage;
Measure essential PROs ongoing with 
treatment  (potentially at every visit)
More comprehensive 
annual evaluation
Fig. 2 Follow-up timeline for
the depression and anxiety
standard set. Proposed and
optional assessment time points
for subsets included in the
ICHOM depression and anxiety
standard set. BL baseline
assessment, TM treatment
monitoring, AA annual
assessment
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biomedical markers. One reason for this is a lack of stan-
dardization. The goal of the present initiative was to rec-
ommend a basic set of outcome assessments for depression
and anxiety disorders that can align existing and newly
developing initiatives and facilitate more global collabo-
ration in the move towards outcome- or value-based
systems.
In contrast to other consensus efforts, patient represen-
tatives (LL, DS) were full members of the working group;
hence, they were involved in the formal development
process of the standard set as well as preparation of the
manuscript. They participated in every teleconference and
the online surveys and had the same voting rights as any
other member of the group. For example, inclusion of
medication side effects for follow-up assessments was
regarded as important by patient representatives and finally
included in the standard set. Thus, patient representatives
were heavily involved in the decision-making process.
Limitations
Group of experts
Our intention was to include a wide spectrum of patient
representatives, clinicians, and researchers from all conti-
nents in our group, resulting in a group of 24 members to
discuss the different steps of this proposal; however, there
are many other well-known scientists, clinicians or patient
representatives that could have provided their valuable
expertise, and different opinions might have been expres-
sed. By extensive literature reviews, and applying a Delphi
technique to document our decision-making process, we
strived to achieve a high level of transparency. Neverthe-
less, like any similar efforts, a different group of partici-
pants could have agreed on different recommendations.
Outcome measures
The main challenge during the entire project was to pro-
pose a set of domains and variables comprehensive enough
to be meaningful but short enough to be implementable on
a large scale and in a variety of settings. With a focus on
feasibility of implementation, we focused on measures
considered to be most helpful in the clinical setting. From a
scientific perspective, a larger set of domains would be of
interest, and we consider this set a foundation upon which
other measures might be added for specific research
questions.
Another limitation is the inclusion of adhoc items, pri-
marily assessing parts of the patients’ medical history to
allow for case-mix adjustment across patient groups.
Including these types of items (i.e., to assess prior episodes
of the disorder or current work status) was essential for the
current value-based approach. Prospectively collected data
over the next years will facilitate validation of the proposed
standard set, which will deliver crucial information on
whether the chosen variables work or whether potential
adjustments are necessary.
During the consensus process, there were extensive
discussions within the working group as to whether the
different depressive disorders such as major depression,
dysthymia, or double depression can be assessed with one
single tool to measure depressive symptoms (i.e., the PHQ-
9), and in particular whether anxiety symptoms from dif-
ferent anxiety spectrum disorders, like General Anxiety
Disorder, Social Anxiety Disorder, Agoraphobia, Panic
Disorder, Post-Traumatic-Stress Disorder, or Obsessive
Compulsive Disorder, can be assessed with another single
tool either (i.e., the GAD-7). To prioritize simplicity and
standardization we recommended, nevertheless, this as the
rather parsimonious approach. The measures proposed to
assess symptom burden, i.e., the PHQ-9 and GAD-7, have
been widely used to assess different disease states and
manifestations of depression and anxiety, respectively [53].
However, we are aware that in particular for patients with
phobic disorders additional questionnaires may be required
to appropriately document the symptom burden of the
individual patient (Online Appendix 8 and 9; online
supplements).
Another important consideration was the accessibility of
the tools worldwide. This criterion excluded many alter-
native tools. However, the suggestion to report the raw
scores of the PHQ-9 and GAD-7 on a common metric
based on modern IRT-methods should allow continued
adoption of future instruments that are compatible with
such an approach. Among several methods to make scores
from different instruments comparable which have been
described in the literature [54, 55], we decided to recom-
mend an IRT-approach as this promises to provide an
instrument-independent metric for many tools at one time
[9], and not just a method to compare one score to another,
like an regression approach. Among the few IRT-based
metrics which are available today, we decided to use the
PROMIS metric, as it received the most public support
over the last decade, and is in our opinion the most likely to
be widely accepted in the future [31, 32]. However, we are
aware that in particular for the more heterogeneous anxiety
construct there are still several scientific issues which are
currently discussed from those applying these methods
[56].
Stakeholders
We recognized from the beginning that a single standard-
ized set cannot meet the expectations of all potential
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stakeholders. Our focus was first on meeting the needs of
practicing clinicians to better communicate with their
patients and assess the impact of their care. Other stake-
holders, such as administrators and economists, may have
preferred metrics that are used across diseases for utility
measurement (e.g., EQ-5D) [57]. For clinicians, utility-
based instruments are insufficiently sensitive to change and
unrelated to the disease construct, making interpretability
and actionability in the clinical context more difficult.
Certainly, research programs wishing to compare utilities
alongside disease-focused impact would be welcome to
add such measures to their battery of assessments.
Evaluation
Measures and items included in the standard set have been
carefully chosen with regard to their psychometric prop-
erties and availability of validation studies. Some new
items had to be adapted or developed to allow for case-mix
adjustment (Table 1), evaluation of these items is pending.
In addition, as the standard set had just been translated into
other languages, future cross-cultural validation studies of
the entire set are warranted. For the main outcome instru-
ments such as PHQ-9, GAD-7, and WHODAS 2.0 avail-
able evidence has already shown cross-cultural validity
[58–61].
Implementation
The Working Group recognized that many implementa-
tion challenges remain to achieve the anticipated impact
of this set. A number of pilot institutions, including
selected members of this Working Group, are currently
implementing the set with the intention of sharing their
experience on the cost and quality impact. In many health
systems, the collection of outcomes data is becoming
more routine through the use of health information tech-
nology, which should facilitate the adoption of these
recommendations. Moreover, in health systems with low
adoption of such technologies, paper and pencil still
provides a cheap and effective mode of data capture. The
recommendation of license-free measures further supports
adoption.
Conclusion
Through the efforts reported in this paper, we defined a
parsimonious set of patient-reported outcome measures
recommended to be applied in patients with depression and
anxiety disorders. We hope this can become an important
step towards improving the quality and value of care for
persons living with depression and anxiety around the
world.
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